1. Evaluation of Exenatide ER (Bydureon) on the duration of diabetic remisison in cats
|Title||Evaluation of Exenatide ER (Bydureon) on the duration of diabetic remisison in cats|
|Contact Person||Audrey Cook, Dip ACVIM (Internal Medicine); Dip ABVP (Feline Practice)
Hospital Phone: 979-845-2351
|Inclusion Criteria and General Background Information||Cats with a recent history (4-12 weeks) of diabetic remission.
Remission is defined as a blood glucose <200 mg/dl for >2 weeks without insulin administration.
|Exclusion Criteria||Cats with severe concurrent disease(s) are not eligible for this trial.|
|Owner Commitments||Cats will be examined at the hospital once a month and given either Exenatide ER or placebo by subcutaneous injection. Trial duration is 12 months or the recurrence of diabetes mellitus (which ever is sooner).|
|Financial Incentives||There is no cost for participation in this trial.
Cats will receive a full evaluation at the time of enrollment, which will include blood and urine testing. Expenses associated with every examination and all diagnostic testing will be covered by the trial. There is no costs associated with administration of Exenatide or placebo.
There are no financial benefits for participation in this trial.
This trial is currently open!
2. Phase II Rapamycin Clinical Trial
|Title||Phase II Rapamycin Clinical Trial|
|Contact Person||Jaime Brannan
|Inclusion Criteria and General Background Information||50 dogs are required to complete the study
・Dogs must be healthy and cooperative for physical exam.
・Dogs must be 6-10 years old, and 40-80 pounds in size.
・Dogs must be heartworm test negative and receiving consistent heartworm prevention.
・Medical history, physical examination and blood and urine tests will be used to determine health status.The study duration is one year, and all dogs will be enrolled in College Station, Texas. Enrolled dogs will be randomized to receive rapamycin or placebo for 6 months, and monitored for a year. Dogs will be examined 4 times over the course of the year and owners will complete health-related questionnaires at each study-related visit and periodically throughout the year.***Enrollment for this study is currently suspended. Please check back later for updates on enrollment***
|Exclusion Criteria||More than 50 dogs will be screened for enrollment and dogs will be excluded if:
・They are not cooperative for physical or cardiac exam.
・Evidence of systemic illness is found on history, physical examination or blood and urine tests.
|Owner Commitments||Owners must be able to:
・Attend 4 scheduled veterinary visits in College Station over the period of one year.
・Administer study medication (rapamycin or placebo) as directed for 6 months.
・Complete periodic surveys and questionnaires about their dogs, as well as keep a diary of drug administration.
|Financial Incentives||The costs of all four veterinary visits, including cardiac examinations, diagnostic testing, and study drug, will be covered by the study.|
3. Evaluation of an oral low-dose dexamethasone suppression test using urine cortisol: creatinine ratio in dogs with suspected hyperadrenocorticism.
Evaluation of an oral low-dose dexamethasone suppression test using urine cortisol: creatinine ratio in dogs with suspected hyperadrenocorticism.
|Inclusion Criteria and General Background Information:
· Client owned dogs with a high clinical suspicion for hyperadrenocorticism.
· Patients must have a complete blood count, chemistry, urinalysis and abdominal ultrasound.
Diagnosis of hyperadrenocorticism can be difficult as no available diagnostic test is perfect. The low dose dexamethasone suppression test is currently the screening test of choice. However, this diagnostic test requires an intravenous injection, the collection of several blood specimens via venipuncture as well as 8 hours of hospitalization. It is known that stress can impact the results of this diagnostic test and potentially lead to misdiagnosis. The purpose of this study would be to demonstrate the efficacy of an at home oral low dose dexamethasone test in the diagnosis of canine hyperadrenocorticism as compared to the ACTH stimulation test and traditional LDDS test. As this is all done in the home, this test will be less stressful for the patient and we hypothesize the oral-LDDS test will be more specific than the traditional LDDS test and lead to more appropriate diagnosis of hyperadrenocorticism.
· Dogs who have been treated with short-acting glucocorticoid within the previous 2 days, or a long-acting glucocorticoid within the previous 3 months.
· Dogs on other medications will be considered on a case by case basis.
The owner will be asked to collect three baseline urine samples on three mornings. Then the owner’s will be instructed to give the pet a capsule containing either dexamethasone or placebo every night at bedtime for 7 consecutive days. They will then be asked to collect a free catch urine the following morning.
The owner will be responsible for initial diagnostics including CBC, chemistry, urinalysis and imaging.
If eligible, the cost of endocrine testing including a low dose dexamethasone test and ACTH stimulation test will be covered by the trial.
4. A Treatment Trial for Cats with Chronic Pancreatitis
|Title:||A treatment trial for cats with chronic pancreatitis|
|Inclusion Criteria and General Background Information:||The purpose of this study is to compare the efficacy of two medications (prednisolone and cyclosporine) for the treatment of chronic pancreatitis in cats.
Cats of any age, breed, or sex are eligible to be enrolled if they meet the following criteria:
1) Diagnosis of pancreatitis with clinical signs lasting for > 2 weeks
2) Serum fPLI >10 μg/L with serum normal cobalamin and folate concentrations
The study duration will be range from 3-5 weeks.
|Exclusion Criteria:||1) Cats that have undergone a diet change in the 2 weeks prior to enrollment
2) Cats that have any concurrent systemic illness or have received past treatment with any medication that might cause pancreatitis.
|Owner Commitments||During the study, cats will be evaluated by a veterinarian three times; once before treatment is started, a second time after 10 days of treatment, and once again after 21 days of treatment. Owners will remain responsible for the cost of all three veterinary visits.
|Financial Incentives:||We will supply prednisolone or cyclosporine for 3 weeks of the study period at no charge. The prescribing veterinarian will be reimbursed for the cost of either medication.
For enrolled patients for which we receive completed evaluation forms, we offer the following tests up to 3 times for each patient (before treatment is started, after 10 days of treatment, and after 21 days of treatment) free of charge:
1) GI panel (serum cobalamin, folate, fTLI and fPLI)
2) All shipping costs related to sending these samples to our laboratory
5. Cyclosporine as a novel therapy for dogs with chronic pancreatitis and diabetes mellitus
|Title:||Cyclosporine as a novel therapy for dogs with chronic pancreatitis and diabetes mellitus|
|Gastrointestinal Laboratory (Dr. Sue Yee Lim)
|Inclusion Criteria and General Background Information:||The purpose of this study is to evaluate the effectiveness of cyclosporine (a drug that suppresses the immune system) for the treatment of dogs with chronic pancreatitis and diabetes mellitus.
Dogs suspected of having chronic pancreatitis and diabetes mellitus (based on clinical evaluation including history, physical examination, and blood tests) are eligible.
|Exclusion Criteria:||Cyclosporine treatment is contraindicated in patients with an infection, cancer, and liver or kidney disease.|
|Owner Commitments||Each patient will participate in this study for a period of six weeks, during which they will receive cyclosporine therapy by mouth on a daily basis. During the participation, the dog will need to be evaluated by its veterinarian two times, once before the treatment is started and once at the end of the 6-week treatment period.|
|Financial Incentives:||The owner will receive cyclosporine therapy for the six weeks of the study for free.|
6. Determination of the clinical utility of novel inflammatory markers dogs with gastrointestinal disease
|Title:||Determination of the clinical utility of novel inflammatory markers dogs with gastrointestinal disease|
|Inclusion Criteria and General Background Information:||Dogs that are presented for clinical signs of gastrointestinal disease and are undergoing a gastrointestinal biopsy as part of their normal diagnostic work-up are eligible for participation.
The purpose of this project is to determine the concentrations of some new markers of inflammatory disease of the gut in serum (blood), urine, fecal samples, and gastrointestinal biopsies from dogs with gastrointestinal disease.
|Exclusion Criteria:||Dogs receiving immunomodulatory drug treatments such as prednisolone are not eligible for enrollment.|
|Owner Commitments||Owners must be willing to collect feces at home from three consecutive bowel movements and store them in a freezer until the time of the office visit or they are shipped to the Gastrointestinal Laboratory by overnight courier.|
|Financial Incentives:||The owner will be responsible for all costs associated with the diagnosis and treatment of the disease process for which their dog is being presented. For eligible patients that are enrolled, the study will pay for the following items on receipt of a full sample set and completed forms.
· Measurement of serum concentrations of cobalamin, folate, TLI, PLI, gastrin, and c-reactive protein
· Fecal Dysbiosis Index
· Fecal alpha1-proteinase inhibitor concentrations
· Histopathological assessment of biopsy specimens through the GI Lab (performed by pathologists with special expertise in evaluation of gastrointestinal specimens)
· All shipping costs related to sending the samples to our lab